Published in J Cell Biochem on October 11, 2001
Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β. J Biol Chem (2013) 1.11
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res (2011) 1.05
Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol Endocrinol (2008) 1.00
The effects of 17-β estradiol on enhancing proliferation of human bone marrow mesenchymal stromal cells in vitro. Stem Cells Dev (2010) 0.86
Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. J Cell Biochem (2008) 0.86
Expression of the human oestrogen receptor-alpha gene is regulated by promoter F in MG-63 osteoblastic cells. Biochem J (2003) 0.81
Cyclin G2 suppresses estrogen-mediated osteogenesis through inhibition of Wnt/β-catenin signaling. PLoS One (2014) 0.79
Estrogen receptor alpha CA dinucleotide repeat polymorphism is associated with rate of bone loss in perimenopausal women and bone mineral density and risk of osteoporotic fractures in postmenopausal women. Osteoporos Int (2007) 0.76
The effect of antineoplastic drugs in a male spontaneous mammary tumor model. PLoS One (2013) 0.75
A cell-biased effect of estrogen in prion infection. J Virol (2013) 0.75
Involutional osteoporosis. N Engl J Med (1986) 8.20
A role for CD95 ligand in preventing graft rejection. Nature (1995) 6.07
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A (1986) 4.51
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab (1998) 4.28
A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res (1998) 4.24
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med (1992) 4.19
TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia (2003) 4.17
beta-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin. Biochemistry (1980) 3.94
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med (1982) 3.77
Weekend hospitalization and additional risk of death: an analysis of inpatient data. J R Soc Med (2012) 3.77
Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest (1981) 3.60
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol (1998) 3.60
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect (1996) 3.34
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem (2000) 3.34
Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low risk population. BMJ (1991) 3.30
Epidemiology of vertebral fractures in women. Am J Epidemiol (1989) 3.27
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop Relat Res (1981) 2.93
Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest (1982) 2.92
Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum (1984) 2.85
Evidence of estrogen receptors in normal human osteoblast-like cells. Science (1988) 2.85
Epidemiologic features of humeral fractures. Clin Orthop Relat Res (1982) 2.79
Direct detection of HIV RNA expression in seropositive subjects. Lancet (1988) 2.75
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74
Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int (2008) 2.72
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65
Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology (1999) 2.65
Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res (1993) 2.59
Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A (1994) 2.41
Secular trends in the incidence of hip fractures. Calcif Tissue Int (1987) 2.40
Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res (1990) 2.39
Molecular diagnosis of infective endocarditis--a new Duke's criterion. Scand J Infect Dis (2001) 2.36
Osteoporosis and the risk of hip fracture. Am J Epidemiol (1986) 2.35
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry (1997) 2.32
Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem (1994) 2.30
Current status of ketamine anaesthesia. Lancet (1971) 2.28
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Which gp160 vaccine? Nature (1993) 2.27
Idiopathic osteoporosis--is the osteoblast to blame? J Clin Endocrinol Metab (1997) 2.25
A new method for radionuclide imaging of myocardial infarcts. Radiology (1974) 2.24
Vertebral fractures predict subsequent fractures. Osteoporos Int (1999) 2.24
Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest (1979) 2.21
Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol (2001) 2.20
Evidence for two distinct syndromes of involutional osteoporosis. Am J Med (1983) 2.17
Incidence of Colles' fracture in a North American community. Am J Public Health (1982) 2.17
Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem (2001) 2.16
Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res (1996) 2.16
Certification, accreditation, and quality control in behavior analysis. Behav Anal (2001) 2.14
Lumbosacral cerebrospinal fluid volume is the primary determinant of sensory block extent and duration during spinal anesthesia. Anesthesiology (1998) 2.09
Oxybenzone oxidation following solar irradiation of skin: photoprotection versus antioxidant inactivation. J Invest Dermatol (1996) 2.07
Laryngeal mask airway for caesarean section. Anaesthesia (1990) 2.05
Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum (1990) 2.03
Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science (1989) 2.03
Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest (1986) 2.01
Risk factors for spinal osteoporosis in men. Am J Med (1983) 2.00
Some historical and conceptual relations among logical positivism, operationism, and behaviorism. Behav Anal (1985) 1.99
Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol (1996) 1.99
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res (2000) 1.98
Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res (1995) 1.97
Epidemiology of sarcopenia. J Am Geriatr Soc (2000) 1.97
Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol (1996) 1.96
Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol (1998) 1.95
Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology (1999) 1.93
Nonhistone chromosomal proteins and gene regulation. Science (1974) 1.92
Skeletal effects of estrogen. Endocr Rev (1994) 1.91
Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med (1984) 1.90
Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res (1995) 1.89
Classification of vertebral fractures. J Bone Miner Res (1991) 1.89
Pumilio is essential for function but not for distribution of the Drosophila abdominal determinant Nanos. Genes Dev (1992) 1.85